Hjem
Elisabeth Wiks bilde

Elisabeth Wik

Førsteamanuensis, Postdoc
  • E-postElisabeth.Wik@uib.no
  • Telefon+47 55 97 26 78+47 975 39 296
  • Besøksadresse
    Avd for patologi, Haukeland Universitetssjukehus
  • Postadresse
    Postboks 7804
    5020 Bergen

Brystkreft; Molekylære endringer i ulike subgrupper (postdoc-prosjekt)

Genekspresjonsanalyser

Erfaring fra forskning på genekspresjonsforandringer ved endometriecancer (PhD)

PÅGÅENDE UNDERVISNING (2015):

Kordinator for PhD-kurset "CCBIO Junior Symposium" (CCBIO-901).

Timeundervisning ved PhD-kursene "Methods i Cancer Biomarker Research" (CCBIO-905) og "Biomarkers and Tumor Biology in Clinical Practice" (CCBIO-904).

Undervisning i patologi (obduksjon/makro) for medisinerstudenter.

TIDLIGERE UNDERVISNING:

Timeundervisning for medisinerstudenter i Gynekolog og obstetrikk.

Timeundervisning for masterstudenter i ernæringsfysiologi.

Vitenskapelig artikkel
  • Vis forfatter(e) 2021. Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer. The journal of pathology. Clinical research. 517-527.
  • Vis forfatter(e) 2021. Fibulin-2 expression associates with vascular invasion and patient survival in breast cancer. PLOS ONE. 1-14.
  • Vis forfatter(e) 2021. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Scientific Reports. 1-11.
  • Vis forfatter(e) 2020. Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. Scientific Reports. 14 sider.
  • Vis forfatter(e) 2020. MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes. Breast Cancer Research and Treatment. 73-86.
  • Vis forfatter(e) 2019. PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Vis forfatter(e) 2019. Integrin α11β1 is expressed in breast cancer stroma and associates with aggressive tumor phenotypes. The journal of pathology. Clinical research. 69-82.
  • Vis forfatter(e) 2018. Transient elevation of anti-transglutaminase and anti-endomysium antibodies in Giardia infection. Scandinavian Journal of Gastroenterology. 809-812.
  • Vis forfatter(e) 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Vis forfatter(e) 2018. Deblender: A semi-/unsupervised multi-operational computational method for complete deconvolution of expression data from heterogeneous samples. BMC Bioinformatics. 1-17.
  • Vis forfatter(e) 2017. Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer. Human Pathology. 72-80.
  • Vis forfatter(e) 2017. Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLOS ONE. 1-15.
  • Vis forfatter(e) 2017. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Scientific Reports. 1-12.
  • Vis forfatter(e) 2017. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLOS ONE. 1-12.
  • Vis forfatter(e) 2016. Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival. Journal of Clinical Pathology. 313-319.
  • Vis forfatter(e) 2016. Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer. PLOS ONE.
  • Vis forfatter(e) 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Vis forfatter(e) 2015. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • Vis forfatter(e) 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Vis forfatter(e) 2015. Intra-gene DNA methylation variability is a clinically independent prognostic marker in women's cancers. PLOS ONE.
  • Vis forfatter(e) 2015. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • Vis forfatter(e) 2015. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Medicine.
  • Vis forfatter(e) 2014. Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Vis forfatter(e) 2014. Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Vis forfatter(e) 2014. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer.
  • Vis forfatter(e) 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Vis forfatter(e) 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Vis forfatter(e) 2014. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Vis forfatter(e) 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Vis forfatter(e) 2014. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. Diagnostic Pathology. 8 sider.
  • Vis forfatter(e) 2014. An 18-Gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer. PLOS ONE.
  • Vis forfatter(e) 2013. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Medicine.
  • Vis forfatter(e) 2013. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics. 371-384.
  • Vis forfatter(e) 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Vis forfatter(e) 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
  • Vis forfatter(e) 2013. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 sider.
  • Vis forfatter(e) 2013. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • Vis forfatter(e) 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Vis forfatter(e) 2013. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Vis forfatter(e) 2013. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. International Journal of Gynecological Cancer. 1050-1055.
  • Vis forfatter(e) 2013. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications. 10 sider.
  • Vis forfatter(e) 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Vis forfatter(e) 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Vis forfatter(e) 2012. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 sider.
  • Vis forfatter(e) 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Vis forfatter(e) 2012. Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecologic Oncology. 381-387.
  • Vis forfatter(e) 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Vis forfatter(e) 2011. Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research. 3368-3377.
  • Vis forfatter(e) 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Vis forfatter(e) 2011. Evolution in endometrial cancer evidence from an immunohistochemical study. International Journal of Gynecological Cancer. 316-322.
  • Vis forfatter(e) 2011. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clinical Cancer Research. 4825-4833.
  • Vis forfatter(e) 2009. Prognostic Impact of Parity in 493 Uterine Sarcoma Patients. International Journal of Gynecological Cancer. 1062-1067.
  • Vis forfatter(e) 2009. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
  • Vis forfatter(e) 2009. Parity and time interval since childbirth influence survival in endometrial cancer patients. International Journal of Gynecological Cancer. 665-669.
  • Vis forfatter(e) 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • Vis forfatter(e) 2009. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
Leserinnlegg
  • Vis forfatter(e) 2012. Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
  • Vis forfatter(e) 2010. Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) 2017. Cancer Biomarkers: Ethics, Economics and Society. Megaloceros Press.
Doktorgradsavhandling
  • Vis forfatter(e) 2013. Endometrial carcinoma: a step closer to individualized therapy? Exploring transcriptional alterations in relation to prognostic biomarkers.
Intervju
  • Vis forfatter(e) 2017. Med forskning som ståsted i patologien.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) 2017. Gene expression signatures of the tumor microenvironment: relation to tumor progress in breast cancer. 29 sider.
Sammendrag/abstract
  • Vis forfatter(e) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. 18-18.
  • Vis forfatter(e) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
Poster
  • Vis forfatter(e) 2012. Identification of metastasis subnetworks in endometrial cancer.
  • Vis forfatter(e) 2012. An ensemble-based feature selection algorithm for identifying candidate metastasis marker genes in endometrial cancer.
  • Vis forfatter(e) 2009. Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2014. Clinical value of DNA content assessment in endometrial cancer. Cytometry Part B: Clinical Cytometry. 154-163.

Se fullstendig oversikt over publikasjoner i CRIStin.

Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, Stefansson IM, Petersen K, Simon R, Cherniack AD, Meyerson M, Kalland KH, Akslen LA, Salvesen HB.
Gynecol Oncol. 2014 Sep;134(3):599-606. PMID: 24995579

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.
Clin Cancer Res. 2013 May 1;19(9):2331-41. PMID: 23538402

Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
Wik E, Ræder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M, Stefansson IM, Oyan AM, Kalland KH, Akslen LA, Salvesen HB.
Clin Cancer Res. 2013 Mar 1;19(5):1094-105. PMID: 23319822

An 18-gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer.
Mannelqvist M, Wik E, Stefansson IM, Akslen LA.
PLoS One. 2014 Jun 6;9(6):e98787.
PMID: 24905342

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.
Stefansson IM, Raeder M, Wik E, Mannelqvist M, Kusonmano K, Knutsvik G, Haldorsen I, Trovik J, Øyan AM, Kalland KH, Staff AC, Salvesen HB, Akslen LA.
Oncotarget. 2015 Mar 10. PMID: 25860936

Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.
Chen Y, Klingen TA, Wik E, Aas H, Vigeland E, Liestøl K, Garred Ø, Mæhlen J, Akslen LA, Lømo J. Diagn Pathol. 2014 Dec 19;9(1):230. PMID: 25522915

 

For other publications, see: http://www.ncbi.nlm.nih.gov/pubmed/?term=wik+e

 

 

 

 

Postdoc prosjekt:

Biomarkers and gene expression profiles for disease progression across different molecular subtypes of breast cancer